The VHL tumor suppressor protein regulates tumorigenicity of U87-derived glioma stem-like cells by inhibiting the JAK/STAT signaling pathway

Kanno,Hiroshi; Sato,Hidemitsu; Yokoyama,Taka-Akira; Yoshizumi,Tetsuya; Yamada,Sachiko

doi:10.3892/ijo.2013.1773

The VHL tumor suppressor protein regulates tumorigenicity of U87-derived glioma stem-like cells by inhibiting the JAK/STAT signaling pathway

Authors:
- Hiroshi Kanno
- Hidemitsu Sato
- Taka-Akira Yokoyama
- Tetsuya Yoshizumi
- Sachiko Yamada
View Affiliations

Affiliations: Department of Neurosurgery, Yokohama City University School of Medicine, Yokohama, Japan
Published online on: January 16, 2013 https://doi.org/10.3892/ijo.2013.1773
Pages: 881-886

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The signal transducer and activator of transcription 3 (STAT3) factor plays an important role in the tumorigenicity of cancer stem cells. The purpose of this study was to investigate the inhibitory mechanism of this pathway acting through the tumor suppressor von Hippel-Lindau (VHL) protein in glioma cancer stem cells. We isolated floating neurosphere‑forming CD133+ cells as glioma stem-like cells (GSLCs) by the MACS method. Furthermore, we examined these cells for their growth rate, ability to form colonies and neurospheres in soft agar, capacity for implantation into SCID mice and expression of CD133, STAT3, JAK2, Elongin A, PTEN and VHL. Furthermore, we transferred the VHL gene, an inhibitor of STAT3, into GSLCs using an adenovirus vector and compared these transfectants with control vector-transfected GSLCs. GSLCs proved to be implantable and formed a tumor in the subcutaneous tissue of SCID mice, the histology of which was similar to that of human glioblastomas. In addition, GSLCs exhibited a high capacity for soft agar colony and neurosphere formation, nearly all of which were CD133 positive. The majority of GSLCs were immunopositive for STAT3, JAK2 and Elongin A, but immunonegative for PTEN and VHL. When the VHL gene was transferred to GSLCs and these cells were transplanted into SCID mice, they did not result in tumor formation. Their capacity for soft agar colony and neurosphere formation was significantly inhibited, although their proliferation was only moderately inhibited. Regarding the expression of various factors, that of CD133 was decreased in the VHL transfectants and those of STAT3, JAK2 and Elongin A were eliminated. However, the expression of PTEN and of VHL was upregulated. These findings suggest that VHL regulated the tumorigenicity and self‑renewal ability of glioma cancer stem cells by inhibiting the JAK/STAT signaling pathway.

View Figures

View References

1	Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
2	Friedman HS, Prados MD, Wen PY, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 27:4733–4740. 2009. View Article : Google Scholar : PubMed/NCBI
3	Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB: Identification of human brain tumour initiating cells. Nature. 432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
4	Yu SC, Ping YF, Yi L, Zhou ZH, Chen JH, Yao XH, Gao L, Wang JM and Bian XW: Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett. 265:124–134. 2008. View Article : Google Scholar : PubMed/NCBI
5	Sherry MM, Reeves A, Wu JK and Cochran BH: STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells. 27:2383–2392. 2009. View Article : Google Scholar : PubMed/NCBI
6	Villalva C, Martin-Lannerée S, Cortes U, Dkhissi F, Wager M, Le Corf A, Tourani JM, Dusanter-Fourt I, Turhan AG and Karayan-Tapon L: STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy? Int J Cancer. 128:826–838. 2011. View Article : Google Scholar : PubMed/NCBI
7	Yang YP, Chang YL, Huang PI, et al: Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J Cell Physiol. 227:976–993. 2012. View Article : Google Scholar : PubMed/NCBI
8	Ohno M, Natsume A, Kondo Y, Iwamizu H, Motomura K, Toda H, Ito M, Kato T and Wakabayashi T: The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma. Mol Cancer Res. 7:2022–2030. 2009. View Article : Google Scholar : PubMed/NCBI
9	Ivanov SV, Salnikow K, Ivanova AV, Bai L and Lerman MI: Hypoxic repression of STAT1 and its downstream genes by a pVHL/HIF-1 target DEC1/STRA13. Oncogene. 26:802–812. 2007. View Article : Google Scholar : PubMed/NCBI
10	Kamura T, Sato S, Haque D, Liu L, Kaelin WG Jr, Conaway RC and Conaway JW: The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 12:3872–3881. 1998. View Article : Google Scholar : PubMed/NCBI
11	Dasari VR, Kaur K, Velpula KK, Gujrati M, Fassett D, Klopfenstein JD, Dinh DH and Rao JS: Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. PLoS One. 5:e103502010. View Article : Google Scholar : PubMed/NCBI
12	Frew IJ, Thoma CR, Georgiev S, Minola A, Hitz M, Montani M, Moch H and Krek W: pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J. 27:1747–1757. 2008. View Article : Google Scholar : PubMed/NCBI
13	Bar EE: Glioblastoma, cancer stem cells and hypoxia. Brain Pathol. 21:119–129. 2011. View Article : Google Scholar : PubMed/NCBI
14	Qiu B, Sun X, Zhang D, Wang Y, Tao J and Ou S: TRAIL and paclitaxel synergize to kill U87 cells and U87-derived stem-like cells in vitro. Int J Mol Sci. 13:9142–9156. 2012. View Article : Google Scholar : PubMed/NCBI
15	Yamada H, Dezawa M, Shimazu S, Baba M, Sawada H, Kuroiwa Y, Yamamoto I and Kanno H: Transfer of the von Hippel-Lindau tumor suppressor gene to neuronal progenitor cells in treatment for Parkinson’s disease. Ann Neurol. 54:352–359. 2003.PubMed/NCBI
16	Hägerstrand D, He X, Bradic Lindh M, Hoefs S, Hesselager G, Ostman A and Nistér M: Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile. Neuro Oncol. 13:1178–1191. 2011.
17	Kanno H, Kuwabara T, Shinonaga M, Chang CC, Tanaka Y, Sugio Y, Morita H, Yasumitsu H, Umeda M and Nagashima Y: Establishiment of a human glioma cell line bearing a homogeneously staining chromosomal region and releasing α- and β-type transforming growth factors. Acta Neuropathol. 79:30–36. 1989.PubMed/NCBI
18	Yamada S, Kanno H and Kawahara N: Trans-membrane peptide therapy for malignant glioma by use of a peptide derived from the MDM2 binding site of p53. J Neurooncol. 109:7–14. 2012. View Article : Google Scholar : PubMed/NCBI
19	Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW and Holland EC: PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 4:226–235. 2009. View Article : Google Scholar : PubMed/NCBI
20	Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER and Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:271–275. 1999. View Article : Google Scholar : PubMed/NCBI
21	Kanno H, Shuin T, Kondo K, Yamamoto I, Ito S, Shinonaga M, Yoshida M and Yao M: Somatic mutations of the von Hippel-Lindau tumor suppressor gene and loss of heterozygosity on chromosome 3p in human glial tumors. Cancer Res. 57:1035–1038. 1997.PubMed/NCBI
22	Sun X, Liu M, Wei Y, Liu F, Zhi X, Xu R and Krissansen GW: Overexpression of von Hippel-Lindau tumor suppressor protein and antisense HIF-1alpha eradicates gliomas. Cancer Gene Ther. 13:428–435. 2006. View Article : Google Scholar : PubMed/NCBI
23	Valk PE, Mathis CA, Prados MD, Gilbert JC and Budinger TF: Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med. 33:2133–2137. 1992.PubMed/NCBI